{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:34:01Z","timestamp":1762508041231,"version":"3.44.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.radonc.2020.02.022","type":"journal-article","created":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T18:11:56Z","timestamp":1585332716000},"page":"8-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Perspectives on the model-based approach to proton therapy trials: A retrospective study of a lung cancer randomized trial"],"prefix":"10.1016","volume":"147","author":[{"given":"Aimee L.","family":"McNamara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2193-0480","authenticated-orcid":false,"given":"David C.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadya","family":"Shusharina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Ajdari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radhe","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongxing","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Paganetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2020.02.022_b0005","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.ijrobp.2006.01.052","article-title":"Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer","volume":"65","author":"Chang","year":"2006","journal-title":"Radiat Oncol Biol"},{"key":"10.1016\/j.radonc.2020.02.022_b0010","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.cllc.2011.03.027","article-title":"Proton radiation therapy offers reduced normal lung and bone marrow exposure for patients receiving dose-escalated radiation therapy for unresectable stage iii non-small-cell lung cancer: a dosimetric study","volume":"12","author":"Nichols","year":"2011","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.radonc.2020.02.022_b0015","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrclinonc.2013.79","article-title":"Charged particle therapy\u2014optimization, challenges and future directions","volume":"10","author":"Loeffler","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.radonc.2020.02.022_b0020","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.ijrobp.2017.01.236","article-title":"Predicting patient-specific dosimetric benefits of proton therapy for skull-base tumors using a geometric knowledge-based method","volume":"97","author":"Hall","year":"2017","journal-title":"Radiat Oncol Biol"},{"key":"10.1016\/j.radonc.2020.02.022_b0025","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3109\/0284186X.2012.718093","article-title":"A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis","volume":"51","author":"Vogelius","year":"2012","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2020.02.022_b0030","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/PPO.0b013e3181b6127c","article-title":"Current clinical evidence for proton therapy","volume":"15","author":"Brada","year":"2009","journal-title":"Cancer J"},{"key":"10.1016\/j.radonc.2020.02.022_b0035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.radonc.2012.01.003","article-title":"Charged particles in radiotherapy: a 5-year update of a systematic review","volume":"103","author":"De Ruysscher","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.02.022_b0040","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.radonc.2012.02.001","article-title":"An evidence based review of proton beam therapy: the report of ASTRO's emerging technology committee","volume":"103","author":"Allen","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.02.022_b0045","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.semradonc.2012.11.005","article-title":"Health economic controversy and cost-effectiveness of proton therapy","volume":"23","author":"Lievens","year":"2013","journal-title":"Sem Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.02.022_b0050","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijrobp.2016.10.045","article-title":"Establishing evidence-based indications for proton therapy: an overview of current clinical trials","volume":"97","author":"Mishra","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.02.022_b0055","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1200\/JCO.2017.74.0720","article-title":"Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small-cell lung cancer","volume":"36","author":"Liao","year":"2018","journal-title":"JCO"},{"key":"10.1016\/j.radonc.2020.02.022_b0060","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.radonc.2013.05.007","article-title":"Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach","volume":"107","author":"Langendijk","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.02.022_b0065","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1200\/JCO.2007.14.4329","article-title":"Should randomized clinical trials be required for proton radiotherapy?","volume":"26","author":"Goitein","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.02.022_b0070","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1200\/JCO.2008.16.5514","article-title":"Proton therapy should be tested in randomized trials","volume":"26","author":"Macbeth","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.02.022_b0075","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.radonc.2007.12.024","article-title":"Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No","volume":"86","author":"Suit","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.02.022_b0080","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.radonc.2008.01.012","article-title":"Randomized controlled trials in health technology assessment: overkill or overdue?","volume":"86","author":"Bentzen","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.02.022_b0085","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijrobp.2015.10.004","article-title":"The quest for evidence for proton therapy: model-based approach and precision medicine","volume":"95","author":"Widder","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.02.022_b0090","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.semradonc.2017.11.008","article-title":"Clinical trial strategies to compare protons with photons","volume":"28","author":"Langendijk","year":"2018","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.02.022_b0095","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.radonc.2016.08.022","article-title":"Toward a model-based patient selection strategy for proton therapy: external validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort","volume":"121","author":"Blanchard","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.02.022_b0100","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.radonc.2019.09.017","article-title":"Cross-modality applicability of rectal normal tissue complication probability models from photon-to proton-based radiotherapy","volume":"142","author":"Perdersen","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.02.022_b0105","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1080\/0284186X.2017.1355113","article-title":"Impact of model and dose uncertainty on model-based selection of oropharyngeal cancer patients for proton therapy","volume":"56","author":"Bijman","year":"2017","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2020.02.022_b0110","unstructured":"ClincialTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Trial of image-guided adaptative conformal photon vs proton therapy, with concurrent chemotherapy, for locally advanced non-small cell lung carcinoma: treatment related pneumonitis and locoregional recurrence; Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00915005."},{"key":"10.1016\/j.radonc.2020.02.022_b0115","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ijrobp.2006.07.1337","article-title":"Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non\u2013small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT)","volume":"66","author":"Wang","year":"2006","journal-title":"Radiat Oncol Biol"},{"key":"10.1016\/j.radonc.2020.02.022_b0120","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.ijrobp.2009.06.091","article-title":"Radiation dose-volume effects in the lung","volume":"76","author":"Marks","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.02.022_b0125","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3109\/0284186X.2013.820341","article-title":"Towards individualized dose constraints: adjusting the QUANTEC radiation pneumonitis model for clinical risk factors","volume":"53","author":"Appelt","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2020.02.022_b0130","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ijrobp.2012.03.052","article-title":"Predicting pneumonitis risk: a dosimetric alternative to mean lung dose","volume":"85","author":"Tucker","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.02.022_b0135","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.radonc.2019.05.011","article-title":"Toward personalized dose-prescription in locally advanced non-small cell lung cancer: validation of published normal tissue complication probability models","volume":"138","author":"Thor","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.02.022_b0140","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2005.03.021","article-title":"Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy","volume":"75","author":"Belderbos","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.02.022_b0145","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.radonc.2018.07.021","article-title":"External validation of an NTCP model for acute esophageal toxicity in locally advanced NSCLC patients treated with intensity-modulated (chemo-)radiotherapy","volume":"129","author":"Dankers","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.02.022_b0150","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.radonc.2005.10.001","article-title":"Normal tissue complication probability modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer","volume":"77","author":"Chapet","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.02.022_b0155","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0167-8140(00)00166-3","article-title":"Long-term cardiac mortality following radiation therapy for Hodgkin's disease: analysis with the relative seriality model","volume":"55","author":"Eriksson","year":"2000","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.02.022_b0160","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1259\/0007-1285-69-825-839","article-title":"Long-term cardiac mortality after radiotherapy of breast cancer\u2013application of the relative seriality model","volume":"69","author":"Gagliardi","year":"1996","journal-title":"BJR"},{"key":"10.1016\/j.radonc.2020.02.022_b0165","doi-asserted-by":"crossref","first-page":"942","DOI":"10.21037\/jtd.2016.03.64","article-title":"Limiting the risk of cardiac toxicity with esophageal-sparing intensity modulated radiotherapy for locally advanced lung cancers","volume":"8","author":"Woodford","year":"2016","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.radonc.2020.02.022_b0170","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.ijrobp.2009.04.093","article-title":"Radiation dose-volume effects in the heart","volume":"76","author":"Gagliardi","year":"2010","journal-title":"Radiat Oncol Biol"},{"key":"10.1016\/j.radonc.2020.02.022_b0175","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.radonc.2017.12.027","article-title":"Differences in lung injury after IMRT or proton therapy assessed by 18FDG PET imaging","volume":"128","author":"Shusharina","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.02.022_b0180","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ijrobp.2018.09.029","article-title":"Validation of effective dose as a better predictor of radiation pneumonitis risk than mean lung dose: secondary analysis of a randomized trial","volume":"103","author":"Tucker","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.02.022_b0185","first-page":"20190334","article-title":"Modelling variable proton relative biological effectiveness for treatment planning","volume":"5","author":"McNamara","year":"2019","journal-title":"BJR"},{"key":"10.1016\/j.radonc.2020.02.022_b0190","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ijrobp.2014.12.046","article-title":"Lung cancer cell line screen links fanconi anemia\/BRCA pathway defects to increased relative biological effectiveness of proton radiation","volume":"91","author":"Liu","year":"2015","journal-title":"Radiat Oncol Biol"},{"key":"10.1016\/j.radonc.2020.02.022_b0195","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ijrobp.2018.03.037","article-title":"Asymptomatic late-phase radiographic changes among chest-wall patients are associated with a proton RBE exceeding 1.1","volume":"101","author":"Underwood","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814020301031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814020301031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:09:15Z","timestamp":1759122555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814020301031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":39,"alternative-id":["S0167814020301031"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2020.02.022","relation":{},"ISSN":["0167-8140"],"issn-type":[{"type":"print","value":"0167-8140"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perspectives on the model-based approach to proton therapy trials: A retrospective study of a lung cancer randomized trial","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2020.02.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}